Abstract Purpose: ABT-888, currently in phase 2 trials, is a potent oral poly(ADP-ribose) polymerase inhibitor that enhances the activity of multiple DNA-damaging agents, including temozolomide (TMZ). We investigated ABT-888+TMZ combination therapy in multiple xenograft models representing various human tumors having different responses to TMZ. Experimental Design: ABT-888+TMZ efficacy in xenograft tumors implanted in subcutaneous, orthotopic, and metastatic sites was assessed by tumor burden, expression of poly(ADP-ribose) polymer, and O 6 -methylguanine methyltransferase (MGMT). Results: Varying levels of ABT-888+TMZ sensitivity were evident across a broad histologic spectrum of models (55-100% tumor growth inhibition) in B-cell lymphoma, small cell lung carcinoma, non-small cell lung carcinoma, pancreatic, ovarian, breast, and prostate xenografts, including numerous regressions. Combination efficacy in otherwise TMZ nonresponsive tumors suggests that TMZ resistance may be overcome by poly(ADP-ribose) polymerase inhibition. Profound ABT-888+TMZ efficacy was seen in experimental metastases models that acquired resistance to TMZ. Moreover, TMZ resistance was overcome in crossover treatments, indicating that combination therapy may overcome acquired TMZ resistance. Neither tumor MGMT, mismatch repair, nor poly(ADP-ribose) polymer correlated with the degree of sensitivity to ABT-888+TMZ. Conclusions: Robust ABT-888+TMZ efficacy is observed across a spectrum of tumor types, including orthotopic and metastatic implantation. As many TMZ nonresponsive tumors proved sensitive to ABT-888+TMZ, this novel combination may broaden the clinical use of TMZ beyond melanoma and glioma. Although TMZ resistance may be influenced by MGMT, neither MGMT nor other mechanisms of TMZ resistance (mismatch repair) precluded sensitivity to ABT-888+TMZ. Underlying mechanisms of TMZ resistance in these models are not completely understood but likely involve mechanisms independent of MGMT. (Clin Cancer Res 2009;15(23):7277-90) ABT-888 is a new poly(ADP-ribose) polymerase (PARP) inhibitor with excellent potency (K I , 5.2 and 2.9 nmol/L, PARP-1/ PARP-2) and oral bioavailability (1). As shown previously, ABT-888 enhanced the activity of multiple DNA-damaging agents, including cisplatin, carboplatin, cyclophosphamide, irinotecan, radiation, and temozolomide (TMZ), in various xenograft and syngeneic preclinical models (2). In this study, we evaluated in detail the activity of TMZ and the ability of ABT-888 to enhance TMZ antitumor activity in multiple xenograft tumors implanted in subcutaneous, orthotopic, and metastatic sites.
strategy for cancer (9) . In addition, PARP has been implicated in DSB repair (10) . The absence of PARP can lead to persistent and lethal DSBs resulting from unrepaired single-strand breaks encountered by the replication fork in cells deficient for DSB repair or homologous recombination repair mediated by BRCA1/2 (11-13). Furthermore, evidence for an alternate pathway to nonhomologous end joining in DSB repair can also be dependent on PARP and other BER proteins.
TMZ is an alkylating agent approved for anaplastic astrocytoma and newly diagnosed glioblastoma (14) that has also exhibited clinical activity in metastatic melanoma (15) . It is currently under clinical investigation for multiple indications, including leukemia, lymphoma, aerodigestive tract, pancreatic, and neuroendocrine tumors. TMZ induces DNA methylation of guanine at O 6 (O 6 -MeG, the most cytotoxic lesion that accounts for ∼5% of the lesions) and causes other less cytotoxic lesions, guanine at N 7 (N 7 -MeG, 70%) and adenine at N 3 (N 3 -MeA, 9%; refs. 16, 17) . The N 3 -MeA and N 7 -MeG adducts are rapidly repaired by BER, but during replication, O 6 -MeG incorrectly pairs with thymine and triggers the mismatch repair (MMR) system leading to futile cycles of repair, generating DSBs that result in arrest and apoptosis (16, 17) . A deficiency in MMR leads to tolerance of O 6 -MeG, resulting in cell survival despite persistent DNA damage (18) . Removal of alkylation damage mediated by the DNA repair protein O 6 -alkylguanine-DNA alkyltransferase [O 6 -methylguanine methyltransferase (MGMT)] is also a mechanism of TMZ resistance (19) . Disruption of BER through inhibition of PARP will block the repair of the N 3 -MeA and N 7 -MeG adducts, rendering them toxic and overcoming the above mechanisms of TMZ resistance.
Although TMZ has shown promise in melanoma and glioma, its clinical effectiveness is hampered by development of chemoresistance (14) . MGMT levels and MMR deficiency are factors clinically implicated in TMZ resistance. As MGMT is rapidly inactivated on transfer of the alkyl group from the O 6 -MeG adducts, this has led to evaluation of protracted dosing regimens to deplete MGMT activity as a strategy to overcome resistance. Although high levels of MGMT are prevalent in tumors (20) and associated with TMZ resistance in vitro and in vivo (21) , clinical studies have not always shown a clear association of low MGMT activity (by methylation or expression) with better response or prognosis (14, 22) , suggesting the existence of other resistance mechanisms. To date, pseudosubstrates of MGMT are being exploited as a therapeutic strategy to increase TMZ effectiveness and potentially overcome resistance by depleting MGMT (23, 24) . PARP inhibition has been shown to overcome TMZ resistance in MMR-deficient cells (16, 25) and represents an attractive strategy for reversing additional mechanisms of TMZ resistance.
Results presented here show the ability of ABT-888 to enhance TMZ activity in a broad spectrum of tumor types. Efficacy was not dependent on sensitivity to TMZ, as tumors initially refractory to TMZ showed a significant antitumor response to ABT-888+TMZ combination therapy. Of 10 models tested, TMZ was effective in 7, all of which eventually acquired resistance to TMZ. Three models showed very little TMZ monotherapy efficacy. In contrast, ABT-888+TMZ was significantly active in all 10 models [6 showed profound efficacy with >90% tumor growth inhibition (TGI)]. Furthermore, in a subcutaneous and intratibial model, acquired resistance to TMZ monotherapy could be overcome by the addition of ABT-888 to TMZ in crossover treatment for a second cycle of therapy. In a second model, the efficacy of ABT-888+TMZ not only affected the primary tumor but also suppressed development of spontaneous lung metastases. Potential determinants of the in vivo response were evaluated; tumor poly(ADP-ribose) polymer (PAR) as well as MGMT expression did not correlate with in vivo sensitivity, suggesting MGMT-independent mechanisms of TMZ resistance.
Materials and Methods
Compound. Enantiomerically pure ABT-888 was synthesized at Abbott. The synthesis and cell-based evaluation is published elsewhere (1, 8) .
Cell lines for in vivo studies. Capan-1 and Calu-6 were obtained from the American Type Culture Collection, HeyA8 and MDA-231-LC3 from M. D. Anderson, and NCI-H526 from the National Cancer Institute Department of Tumor Repository. The Capan-1 cells and tumors used in our studies were confirmed to harbor the published 6174delT deletion mutation resulting in BRCA2 deficiency (data not shown; ref. 26) . All lines were cultured in RPMI 1640 with 10% fetal bovine serum (FBS; Hyclone), except HeyA8 and MDA-231-LC3 (DMEM with 10% FBS) and Capan-1 (Iscove's modified Dulbecco's medium with 20% FBS). DOHH-2 was purchased from the Deutsche SammLung von Mikroorganismen und Zellkulturen and cultured in RPMI 1640 (Invitrogen) supplemented with nonessential amino acids (Invitrogen) and 10% FBS. Cells were maintained at 37°C in a humidified atmosphere equilibrated with 5% CO 2 , 95% air, confirmed to be free of Mycoplasma, and used between passages 3 and 7 when in log phase for tumor cell inoculation.
The PC3M-Luc-C6 (PC3M-Luc; Caliper Corp.) is a PC3M luciferasetransfected line from an orthotopically, in vivo-selected PC3 line derived from a grade 4 prostate adenocarcinoma bone metastases, and the MDA-MB-231-luc-D3H2LN (MDA-231-Luc; Bioware, Caliper) is a luciferase line derived from a spontaneous lymph node metastases of MDA-MB-231-luc breast cells implanted orthotopically into the mammary fat pad. Both cell lines were cultured in MEM with 10% FBS.
Translational Relevance
ABT-888, a potent poly(ADP-ribose) polymerase (PARP) inhibitor, is currently in phase 2 clinical trials. PARP inhibitors broadly enhance the activity of DNAdamaging agents owing to the critical function of PARP-1 and PARP-2 in base excision repair. Thus, the use of PARP inhibitors to enhance DNA-damaging agents [e.g., temozolomide (TMZ)] shows promise as a therapeutic strategy for cancer. ABT-888+TMZ showed robust antitumor activity in a broad histologic spectrum of subcutaneous, orthotopic, and metastatic xenograft models. These models attempt to recapitulate clinical settings that are difficult to treat and often result in severe morbidity/mortality. In addition, ABT-888+TMZ was efficacious in tumors resistant to TMZ monotherapy (inherent and acquired). Importantly, O 6 -methylguanine methyltransferase expression does not preclude sensitivity to ABT-888+TMZ therapy. Our data define a rational combination regimen with direct clinical application in indications often hampered by resistance to chemotherapies (metastatic disease) and have the potential to positively affect patient outcome.
Xenograft subcutaneous flank studies. All animal studies were conducted in a specific pathogen-free environment in accordance to the internal Institutional Animal Care and Use Committee, accredited by the American Association of Laboratory Animal Care, which meet or exceed the standards set by the U.S. Department of Agriculture Animal Welfare Act, Public Health Service policy on humane care and use of animals, and the NIH guide on laboratory animal welfare. In all studies shown, no significant health concerns were observed (e.g., ≥20% weight loss, ruffled coat, hunched posture, dehydration, and lethargy) unless otherwise noted.
Mice were obtained from Charles River Laboratories at 5 to 6 weeks of age and used when greater than 8 weeks of age and/or ∼20 g in weight. One million cells (2 × 10 6 for Calu-6) were mixed 1:1 with Matrigel (BD Biosciences) and injected s. . Enhancement of TMZ efficacy (%T/C TMZ ) was assessed using tumor growth effect in the TMZ monotherapy group as control (C TMZ ) compared with the TMZ combination group (time point B). %T/C TMZ was assessed at a later time point than %T/C when the vehicle control groups have reached tumor end point and can no longer be analyzed.
X-ray image analysis of tibiae and area of decreased calcification calculation. The tibiae were X-rayed using a Faxitron (Faxitron X-Ray Corp.). The area of decreased calcification (ADC) of tibiae between the knee and fibula joint was analyzed using the Automatic Measurement Program Wizard image analysis program (AxioVision 4, Zeiss). The difference between background calcification of normal tibia and tumor-bearing areas equals the ADC. A reduction in ADC or bone density in the treated groups compared with the vehicle group represents a decrease in osteolytic reaction or tumor burden expressed as % ADC inhibition calculated by the following formula: [vehicle ADCtreated ADC] / vehicle ADC × 100 (i.e., a greater % ADC inhibition, the more effective the treatment). Both the PC3M-Luc and MDA-231-LN-Luc lines result in an osteolytic lesion when implanted in the tibiae.
ABT-888 was administered orally (twice daily for 3-6 days) in a vehicle containing 0.85% NaCl adjusted to pH 4.0 using HCl. TMZ (Schering-Plough) was formulated in 0.2% hydroxypropyl methylcellulose and administered orally (once daily for 5 days) concurrently with ABT-888. Zoledronic acid (ZA; Novartis) was formulated in 0.85% NaCl and administered twice a week.
PAR, MGMT, hMLH1, and hMSH2 Western blot. A reduction in tumor PAR after ABT-888 treatment reflecting the inhibition of PARP activity in vivo (2) and MGMT expression, a potential factor in TMZ resistance mechanism (21), were evaluated by Western blot. Tumors were excised from humanely euthanized mice treated in vivo, as previously described. Tumor lysates were analyzed by immunoblot using SuperSignal West Dura (Pierce). The following rabbit polyclonal antibodies were used: PAR from Trevigen (1:1,000) and MGMT (1:1,000) and β-tubulin (1:1,000) from Cell Signaling Technology. The following mouse monoclonal antibodies were used: hMLH1 (1 μg/mL) from BD Biosciences and hMSH2 (1 μg/mL) from EMD.
Statistical analysis. Differences between groups were analyzed using the Student's t test (two tailed) or ANOVA/Fisher's protected least significant difference for comparing groups with P ≤ 0.05 considered statistically significant.
Results
Significant efficacy of ABT-888+TMZ in various tumor types regardless of TMZ sensitivity. Our previous preclinical studies showed that ABT-888 enhanced the antitumor activity of multiple DNA-damaging agents, including TMZ in vitro (8) and in vivo (2) . Although glioma and melanoma are primary clinical indications for TMZ (27, 28) , we show that ABT-888 (25 mg/ kg/d, orally, twice daily for 5-6 days) enhances TMZ efficacy (50 mg/kg/d, orally, once daily for 5 days) when administered concurrently in tumors from divergent histologic tumor types, including B-cell lymphoma, small cell lung carcinoma, nonsmall cell lung carcinoma, ovarian, breast, pancreatic, and prostate models (Tables 1 and 2 ; Fig. 1 ; Supplementary Data S1). The TMZ dose used in our studies approximates the human clinical exposure (29) . Further, the estimated minimum efficacious dose targeted [ABT-888 doses used in this study (2) ] was achieved in humans and its ability to significantly inhibit PAR in patients was shown (1, 30) . No overt signs of toxicity or significant health concerns were observed other than temporary and recoverable weight loss where noted. In the BRCA2-deficient Capan-1 model, whereas ABT-888 had no single-agent activity at 50 mg/kg/d, moderate TGI was observed at higher doses (≥100 mg/kg/d; data not shown), albeit significantly less than was achieved with the TMZ combination. This result in Capan-1 is consistent with that seen using other PARP inhibitors and likely due to its homologous recombination deficiency (11) (12) (13) 26) . ABT-888 also did not show single-agent activity at 25 mg/kg/d in other models; however, ABT-888+TMZ exhibited significant activity (68-100% TGI ABT-888+TMZ ) compared with vehicle in both solid and hematologic tumor types. Moreover, efficacious combination therapy was not dependent on the initial effectiveness of TMZ monotherapy, suggesting that the degree of TMZ sensitivity was not a predictor of ABT-888 combination activity. In a subset of tumors (Capan-1, DOHH-2, and NCI-H526), TMZ monotherapy activity was minimal (29-41% TGI), yet ABT-888 showed marked in vivo efficacy in combination with TMZ (68-89% TGI ABT-888+TMZ ; Table 1 ). Overall, our results illustrate the broad-spectrum activity of ABT-888+TMZ in a diverse panel of histologic types and show that lack of TMZ single-agent activity does not preclude sensitivity to ABT-888+TMZ combination therapy.
In some cases, significant TMZ monotherapy activity was observed at early time points (HeyA8, orthotopic MDA-231-LC3, and Calu-6; Fig. 1 ; time point A). However, after a period of time, resistance to TMZ or the regrowth of surviving cells after TMZ treatment became evident (HeyA8 and MDA-231-LC3, time point B) and a second cycle of TMZ proved ineffective (Calu-6, time point B). In contrast, the combination of ABT-888+TMZ produced sustained activity in the HeyA8, orthotopic MDA-231-LC3, Capan-1, and Calu-6 models, indicating the ability to not only maintain sensitivity but also induce partial responses (PR; defined as three or more tumor measurements below the size match; Table 1 ). Although similar in size to tumors treated in the first cycle, tumors treated in the second cycle were insensitive to TMZ treatment, supporting the notion of acquired resistance in Calu-6 rather than simply a result of the regrowth from surviving cells. Further, a crossover treatment to combination therapy after the first cycle of TMZ showed profound activity (Calu-6), resulting in PRs similar to that achieved by two cycles of combination therapy, whereas tumors treated with a second cycle of TMZ monotherapy were resistant. These results show the ability of ABT-888+TMZ combination therapy to maintain efficacy in tumors inherently resistant to TMZ and those that acquire TMZ resistance.
Sustained combination therapy efficacy in xenografts implanted in orthotopic and metastatic sites. Clinical resistance to chemotherapy is frequently observed in metastatic tumors (31) . Moreover, the failure to respond to TMZ is attributed to both inherent and acquired resistance mechanisms (32) , similar to the development of the refractory response seen after TMZ treatment in our studies (Fig. 1) . To evaluate the efficacy of ABT-888+TMZ in orthotopic and metastatic settings, several luciferase-labeled lines were implanted in orthotopic or common metastatic sites (intratibial and brain ectopic). The PC3M-Luc human prostate carcinoma was used both orthotopically and intratibially ( Figs. 2 and 4 ; Supplementary Data S2); the MDA-231-LN-Luc, human breast carcinoma, was implanted in the brain ectopically and intratibially (common metastatic sites for breast cancer; Figs. 3 and 5; Supplementary Data S3). Both the orthotopic MDA-231-LC3 ( Fig. 1 ; Table 1 ) and orthotopic PC3M-Luc ( Fig. 2 ; Table 2 ) show marked and equal sensitivity to TMZ monotherapy and ABT-888+TMZ after one cycle of dosing (>90% TGI for TMZ and ABT-888+TMZ). In the orthotopic MDA-231-LC3 model, the substantial improvement in efficacy with ABT-888+TMZ was not evident until at least 13 days after cessation of dosing when TMZ-treated tumors began to grow progressively. Further, ABT-888+TMZ treatment not only showed prolonged regression (80% TGI; P ≤ 0.0001 versus TMZ monotherapy on day 80) but also resulted in 2 of 10 cures (confirmed by histology). In the orthotopic PC3M-Luc model, a second round of treatment at day 42 provided no additional efficacy for TMZ monotherapy, whereas the ABT-888+TMZ maintained continued regression until day 61 (100% TGI; P ≤ 0.05 versus TMZ monotherapy on day 55, time point B) with a significant survival advantage compared with TMZ alone (P ≤ 0.05 versus TMZ monotherapy; Fig. 2C ). Because ABT-888 crosses the blood-brain barrier, we investigated the efficacy of ABT-888+TMZ in the brain. MDA-231-Luc cells were injected ectopically in the brain and monitored for tumor growth (1.3 × 10 7 photons/s, day 11) followed by TMZ or ABT-888+TMZ (Fig. 3A and B) . Significant efficacy was observed with both treatment regimens following the first cycle of therapy. Although resistance to TMZ monotherapy developed during the second treatment cycle, profound efficacy continued to be observed with the ABT-888+TMZ through cycle 3. The effect on tumor growth (tumor sizes remaining below baseline throughout) correlated clearly with the marked improvement in survival to end point seen with combination treatment (100% TGI; P ≤ 0.0001 versus TMZ monotherapy on day 43; Fig. 3C ). Metastatic bone lesions can be osteolytic (PC3M-Luc or MDA-231-Luc) or osteoblastic in nature. Bisphosphonates such as ZA, which inhibit osteoclast action and bone resorption, are current standard of care for patients with bone metastases (33); therefore, ZA was used in conjunction with TMZ and ABT-888 to maintain bone integrity. The addition of ZA to treatments in the intratibial models was well tolerated, and as expected, the X-ray analysis revealed a better maintenance of bone density or reduced ADC in groups receiving ZA ( Fig. 4B ; Supplementary Data S2 and S3). However, ZA monotherapy did not decrease tumor burden or increase survival without the addition of ABT-888 to TMZ treatment. Metastasis to the bone is a common occurrence with advanced prostate and breast cancers (34, 35) ; thus, we assessed the efficacy of ABT-888+TMZ in the bone. The intratibial injection of PC3M-Luc and MDA-231-Luc cells resulted in osteolytic lesions; therefore, tumor burden was evaluated by both BLI and X-ray analysis. As was observed for this tumor in the orthotopic setting (Fig. 2B) , while TMZ monotherapy was initially active, tumors quickly regrew and were resistant to a second cycle of treatment. In contrast, ABT-888+TMZ produced sustained activity through both cycles ( Fig. 4; Table 2 ). Furthermore, following one cycle of TMZ monotherapy, ABT-888+TMZ in the second treatment cycle overcame TMZ resistance. The potent activity of ABT-888+TMZ was also shown by an increase in time to end point by Kaplan-Meier analysis ( Fig. 4C and D ; P ≤ 0.05 versus vehicle or TMZ+ZA).
Likewise, the intratibial MDA-231-Luc model was largely resistant to TMZ monotherapy (0-2% TGI versus vehicle) but was sensitive to ABT-888+TMZ (>60% TGI; P ≤ 0.05 versus vehicle on day 37, time point A; Fig. 5 ; Table 2 ), with regression of tumors continuing through a second cycle of combination therapy (>90% TGI; P ≤ 0.05 versus TMZ monotherapy on day 55, time point B; Fig. 5) .
Interestingly, mice injected intratibially with MDA-231-Luc cells also developed spontaneous lung metastases resulting in mortality after day 42 in the vehicle group (Fig. 5A and B) . Both the TMZ and ABT-888+TMZ groups showed a marked benefit and potent antitumor activity, resulting in regressions of lung metastases. In contrast, acquired TMZ resistance or a significant regrowth of intratibial tumors was observed without the addition of ABT-888 after the second cycle of therapy on day 55 ( Fig. 5B ; Table 2 , time point B). Therefore, TMZ monotherapy and combination treatment seem to be uniformly more effective (with PRs) in the spontaneous lung metastases than in the intratibial tumors within the same mouse and regrowth of lung metastases was not shown until after the second cycle of TMZ. Albeit a small sample size, this finding implies that sensitivity to chemotherapy may be influenced by the site as a reflection of the microenvironment or drug delivery as well as acquisition of molecular changes (MGMT, MMR induction, etc.). Although the nature of this difference in degree of sensitivity to treatment within different organ sites is unclear, our results show that ABT-888+TMZ provided strong efficacy in multiple tissue compartments, including the lung. Overall, these results from two different tissue types (prostate and breast) implanted in different organ sites (orthotopic or metastatic) exhibit the effectiveness of ABT-888+TMZ combination therapy, including tumors that rapidly acquire TMZ resistance.
Significant PAR inhibition in tumors after ABT-888 treatment regardless of sensitivity to ABT-888+TMZ combination therapy. To delineate potential underlying mechanisms of sensitivity to ABT-888+TMZ combination therapy, we initially assessed the inhibition of tumor PAR after ABT-888 treatment in vivo by Western blot (Fig. 6 ). ABT-888 was administered concurrently with TMZ for 3 to 5 days at doses similar to the efficacy studies A, representative BLI. B, corresponding graph. C, Kaplan-Meier analysis based on 1,000% tumor change end point by BLI. A striking increase in survival of the ABT-888+TMZ group when compared with TMZ monotherapy group was evident with none of the mice in the ABT-888+TMZ group reaching end point when the study ended. Points, mean of 9 to 10 mice per treatment group; bars, SEM.
described above and tumors harvested at 2 h after last dose. This treatment schedule and harvest time point was chosen because it correlates with initiation of efficacy and the presence of significant tumor drug levels (36) . We initially examined PAR in representative models where differential enhancement of efficacy was observed with ABT-888 combination therapy compared with TMZ therapy alone (DOHH-2, NCI-H526, Capan-1, and Calu-6). Significant tumor PAR inhibition was observed in all tumor lines after ABT-888 treatment independent of the degree of sensitivity to combination therapy, therefore indicating that ABT-888 effectively inhibits PAR in a diverse array of tumor types. To date, of 12 tumors tested, all express high levels of PAR and treatment with ABT-888 effectively reduces PAR levels in each case (data not shown).
MGMT expression before and after TMZ or ABT-888+TMZ combination therapy indicates MGMT-independent mechanism. Because MGMT is reported to have an important role in TMZ resistance due to its ability to repair DNA methylation, we next sought to determine if the tumor xenograft MGMT status influenced the sensitivity to TMZ and ABT-888+TMZ. Interestingly, the MGMT status of tumors showed no clear correlation to the TMZ sensitivity profile by Western blot (Supplementary Data S4; also confirmed by RNA microarray and methylation status; data not shown). Note that some TMZrefractory xenografts (29-41% TGI) with varying sensitivities to ABT-888+TMZ (68-89% TGI; DOHH-2, NCI-H526, and Capan-1) were found to be MGMT expressing (Fig. 6B ). In contrast, some xenografts were negative or low for MGMT protein but divergent in TMZ sensitivity profiles: initially TMZ sensitive but became insensitive to TMZ and/or acquired TMZ resistance (78-97% TGI; Calu-6, orthotopic and intratibial PC3M, orthotopic MDA-231-LC3, and brain ectopic MDA-231-LN-Luc) or TMZ resistant (2% TGI; intratibial MDA-231-LN-Luc). These results suggest that although MGMT may be a determinant for TMZ resistance in gliomas (14) , MGMT-independent factors may be important in other tumor types. We have also investigated the molecular changes to some extent in the MDA-231-Luc line using accessible tumors and have shown no changes in MGMT expression in tumors implanted s.c. or in the brain (Supplementary Data S5), indicating that although molecular changes such as MGMT may influence sensitivity profiles of cells implanted in different organ sites, the exact mechanisms are not yet clear. More importantly, our results show that ABT-888 can significantly enhance the activity of TMZ in tumors independent of MGMT expression and that MGMT expression does not preclude the ability to achieve marked efficacy with ABT-888+TMZ treatment.
MGMT expression in untreated xenografts may not be truly reflective of the dynamic alkylation repair process; thus, we explored the functional consequence of treatment in vivo to MGMT expression. The subsequent inactivation or degradation of MGMT on transfer of the O 6 -methyl group during DNA Whereas loss of sensitivity to TMZ+ZA is observed after a second cycle, sustained efficacy is observed in the ABT-888+TMZ+ZA groups. Resistance was overcome by treatment with TMZ in the first cycle that crossed over to ABT-888+TMZ+ZA in the second cycle compared with the TMZ+ZA group treated for two cycles. Addition of ABT-888 to TMZ+ZA for two cycles resulted in a striking increase in survival compared with either the vehicle or TMZ+ZA two-cycle groups. Eighty percent of the mice in the triple-combination group did not reach end point at the end of study. Points, mean of 10 mice per treatment group; bars, SEM.
alkylation repair (37) leading to a decrease or depletion of MGMT after treatment may be a better indicator for the role of MGMT in the repair process, hence resistance to treatment. Our results show that although there were changes in MGMT levels, they were minimal; that is, a reduction in MGMT was observed in the MGMT + xenografts after ABT-888+TMZ but did not correlate with the enhanced sensitivity of these lines to ABT-888+TMZ combination treatment (DOHH-2, NCI-H526, Capan-1, and Calu-6). Interestingly, although Calu-6 tumors did not express MGMT initially, significant MGMT was observed after the second cycle (Fig. 6C) . However, tumors of different sizes reflecting treatment effect after the second cycle (tumor size: TMZ, two cycles > TMZ then ABT-888 +TMZ > ABT-888+TMZ, two cycles) show consistent increased levels of MGMT regardless of treatment, further indicating the lack of correlation of MGMT with sensitivity. Furthermore, the tumors effectively treated with two cycles of ABT-888+TMZ showed differential MGMT levels. Nevertheless, MGMT levels observed after treatment did not correlate with the in vivo phenotype, lending support to MGMT-independent mechanisms of resistance.
Discussion
Our results show the potent antitumor efficacy of ABT-888+TMZ across a spectrum of histologic types, where combination efficacy was independent of TMZ activity and can overcome both inherent and acquired TMZ resistance. Although resistance to TMZ may be mediated by MGMT, our results suggest mechanisms independent of MGMT. These data support parallel clinical investigation of ABT-888+TMZ combination therapy in other solid tumors, in addition to glioma and melanoma.
Although the alkylating agent TMZ has a narrow approval for recurrent anaplastic astrocytoma and newly diagnosed glioblastoma (14) , it has shown activity in tumors highly resistant to chemotherapy with poor clinical outcome, thus providing potential significant clinical benefit. However, TMZ efficacy can be hampered by acquired resistance after repeated treatment (15) . Therefore, expanding the clinical indications for TMZ as well as overcoming resistance factors is an attractive strategy for exploiting PARP inhibition. We have previously shown the conversion of single-strand breaks induced by TMZ to more lethal DSBs after PARP inhibition mediated by ABT-888 (8) . Thus, the enhancement of TMZ activity by ABT-888+TMZ was not surprising in TMZ-sensitive models. Interestingly, ABT-888+TMZ was significantly efficacious in most of the models examined, including those that were initially resistant or became resistant to TMZ, indicating that PARP inhibition can confer sensitivity to TMZ-refractory tumors perhaps through BER-mediated repair mechanisms (16, 17, 38) . Therefore, TMZ response was not an absolute predictor of enhanced sensitivity to ABT-888+TMZ combination therapy.
Our studies also show the good tolerability of multiple cycles of ABT-888+TMZ, supporting its feasibility as a combination therapy for the clinic. In a subset of models, evaluation at later time points was necessary because profound TMZ monotherapy activity was initially observed. In these models, the acquired resistance to TMZ monotherapy was evident even after a second treatment cycle (ovarian HeyA8; non-small cell lung carcinoma Calu-6; orthotopic or intratibial prostate; and orthotopic, brain ectopic, or intratibial breast). Strikingly, ABT-888+TMZ showed a marked yet sustained activity and often resulted in PRs after repeated dosing cycles. In two cases where the second cycle of TMZ therapy was ineffective, the crossover treatment from TMZ therapy in cycle 1 to ABT-888+TMZ in cycle 2 afforded substantially increased efficacy (Calu-6 and intratibial prostate). These results indicate potential adaptive mechanisms or selective pressures that result in acquired TMZ resistance and the ability of ABT-888 to overcome this resistance. Moreover, differential efficacy of ABT-888+TMZ treatment in different organ sites was observed and underscores the importance of the microenvironment or tumor-stromal interactions resulting in epigenetic changes, drug penetration, potential ability of a subpopulation to grow/expand in vivo, and/or selection of tumor cells that can influence response to treatment (39, 40) . Interestingly, discordant in vitro and in vivo sensitivity to ABT-888+TMZ was observed (Supplementary Data S6), in support of the important role of many factors mentioned above that can determine in vivo sensitivity. This is the first report of the broad activity of a PARP inhibitor + TMZ therapy in multiple histologic types in subcutaneous and challenging orthotopic or metastases models (including a spontaneous lung metastases model). The ability to overcome resistance and significant efficacy in orthotopic or metastatic sites may have clinical implications for metastatic disease that is often found to be chemoresistant (31) .
The ABT-888 combination response in both the intratibial prostate and breast tumors showed profound combination efficacy that was compatible with bisphosphonate bone-sparing therapy. Although ZA improved bone density, it did not affect tumor growth at the doses used. On the other hand, ABT-888+TMZ exhibited an effect on bone integrity as determined by X-ray analysis and the alleviation of bone decalcification is likely a secondary effect due to the decrease in tumor burden after treatment.
Although identification of factors contributing to combination sensitivity is beyond the scope of this article, we determined if known factors implicated in TMZ resistance correlated with ABT-888 combination sensitivity. The potent inhibition of tumor PARP activity of ABT-888 shown by significant inhibition of PAR in all xenografts coincided with combination sensitivity but did not reflect the degree of sensitivity, pointing to factors other than tumor drug levels. Several mechanisms for TMZ resistance have been proposed that are likely to influence ABT-888 combination sensitivity. Resistance to alkylating agents such as TMZ may be mediated by DNA repair enzymes such as MGMT (repair of O (28, 41, 43) , and the loss of MGMT activity by expression or methylation also correlated with response to alkylation-based therapy (44, 45) . However, our preliminary evaluation yielded no clear correlation of MGMT expression with response to treatment. In addition, O 6 -benzylguanine treatment, an inhibitor of MGMT, was unable to sensitize cells to TMZ in vitro, further supporting mechanisms independent of MGMT (data not shown). These findings are consistent with a recent study showing that MGMT activity and MMR proficiency do not preclude enhancement of TMZ activity by ABT-888 in leukemia primary and cell lines (46) . MGMT, being a suicide enzyme depleted on activation, was minimally decreased in all xenografts after treatment, indicating that MGMT is active in MGMT + lines, although not sufficient to render resistance to therapy. These results are in contrast to recent studies on primary human glioma xenografts where MGMT + lines exhibited resistance to ABT-888+TMZ combination therapy (38) . The underlying reasons for differential sensitivity to ABT-888+TMZ in MGMT + lines are not clear but may reflect tumor type-dependent responses. Nevertheless, our results clearly show potent combination activity and that TMZ resistance (inherent or acquired) as well as MGMT + xenografts do not preclude sensitivity to ABT-888+TMZ combination therapy.
A role for PARP in the regulation of the DNA methyltransferase, DNMT1, and its influence in overall methylation levels have been shown (4), but no significant changes in MGMT after ABT-888 treatment alone were observed, coincident with no known ability of ABT-888 to affect methylation. Regardless of MGMT levels, MMR (MSH2 and MSH6) can play a role in O 6 -MeG tolerance (47) . Although the role of MMR in our system is not yet fully understood, none of the xenografts assessed in our studies are MMR deficient 1 (48) , a profile commonly found in colon lines (Supplementary Data S7; ref. 49) . Another factor, p53, known to suppress MGMT activity predicting TMZ sensitivity (14, 50) , also showed no correlation (DOHH-2 and various p53 wild-type lines exhibited varying levels of sensitivity to TMZ). Our data showed significant reduction in PAR after treatment, indicating potent inhibition of tumor PAR activity. Therefore, the in vivo response phenotype may be mediated by factors influenced by PARP but are independent of BER or alternatively involve potential PARP-independent BER mechanisms. Although the exact roles of potential factors are still unclear, multiple complex mechanisms that determine the in vivo response phenotype may be involved.
We have presented in vivo data that exhibit the robust and potent ability of ABT-888 to increase and maintain TMZ efficacy in several different tumor types. Further, a TMZ-refractory response and MGMT expression do not preclude sensitivity to ABT-888+TMZ combination therapy. Although the determinants of resistance are not fully understood, it may be MGMT (or MMR) independent. Although the clinical indications for TMZ are focused, our results support the evaluation of ABT-888+TMZ effectiveness in multiple human cancer types outside of glioma and melanoma. These models suggest adaptive resistance or selective pressures that result in a refractory response, often a challenge encountered in the clinic that further complicates analysis of clinical resistance mechanisms. Multiple mechanisms of resistance acquired by tumor cells in response to genotoxic stress have limited the effectiveness of chemotherapy (39, 40) . Therefore, chemotherapeutic resistance, de novo or acquired, is a constant challenge in the clinic. Delineating mechanisms and/or determinants for resistance or sensitivity are pivotal in developing therapeutic strategies that positively affect clinical outcome.
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